Annals of Gastroenterology最新文献

{"title":"Endoscopic submucosal dissection for the treatment of early Barrett's neoplasia: long-term outcomes of a prospective multicenter study.","authors":"Guillaume Bergez, Vincent Lépilliez, Thierry Ponchon, Mathieu Pioche, Jérome Rivory, Timothée Wallenhorst, Emmanuel Coron, Nicolas Chapelle, Jérémie Jacques, Romain Legros, Pierre Deprez, Enrique Perez Cuadrado Robles, Arthur Berger, Edouard Chabrun, Geoffroy Vanbiervliet, Stanislas Chaussade, Sarah Leblanc, Romain Coriat, Frédéric Prat, Maximilien Barret","doi":"10.20524/aog.2026.1086","DOIUrl":"10.20524/aog.2026.1086","url":null,"abstract":"<p><strong>Background: </strong>Endoscopic submucosal dissection (ESD) allows for <i>en bloc</i> endoscopic resection of T1 esophageal adenocarcinoma arising on Barrett's esophagus (BE). Although the safety of the procedure is well established, the oncological adequacy of the procedure and the long-term follow up of the patients have not been prospectively studied.</p><p><strong>Methods: </strong>We conducted a prospective, multicenter study involving 9 French and Belgian centers. We included patients treated with ESD for a visible endoscopic lesion of more than 15mm documented with dysplasia, with a 3-year follow up. The primary endpoint was the histologically complete resection rate for adenocarcinoma and high-grade dysplasia (HGD).</p><p><strong>Results: </strong>A total of 141 patients were included in the study between December 2016 and January 2019. The R0 resection rate was 85% for adenocarcinoma and HGD, and 81% for invasive adenocarcinoma. The complication rate was 17%, of which 5% were early complications and 12% were late complications, mainly esophageal strictures. During a median follow-up length of 36.3 months, recurrence was observed in 15% of the patients and was endoscopically manageable in 44%. Eight patients (6%) underwent esophagectomy for a high-risk adenocarcinoma. Overall, 14 patients (12%) died during follow up, 3 of them (2.5%) from esophageal adenocarcinoma.</p><p><strong>Conclusion: </strong>Endoscopic resection by ESD is a safe and effective technique to treat T1 esophageal adenocarcinoma, allowing avoidance of esophagectomy in 94% of the patients.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"39 5","pages":"597-604"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13433957/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148672938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lumen-apposing metal stents versus double pigtail plastic stents for early (<4 weeks of illness) endoscopic transluminal drainage of pancreatic necrotic collections.","authors":"Surinder Singh Rana, Sarakshi Mahajan, Ravi Sharma, Gaurav Sharma, Mandeep Kang, Rajesh Gupta","doi":"10.20524/aog.2026.1031","DOIUrl":"10.20524/aog.2026.1031","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic necrotic collections (PNC) gradually liquefy over time. In the early phase of pancreatitis (<4 weeks), collections contain more solid debris. This study retrospectively compared the safety and efficacy of endoscopic transluminal drainage (ETD) using multiple plastic stents (MPS) vs. lumen-apposing metal stents (LAMS) in early-phase PNC.</p><p><strong>Methods: </strong>A retrospective, single-center, and non-randomized review was conducted of patients who underwent endoscopic ultrasound-guided drainage/debridement of PNC between January 2018 and November 2024. Patients who had early ETD with either MPS or LAMS were included. Data compared included demographics, clinical features, indications, intervention details, need for endoscopic necrosectomy (ETN), complications, need for surgery, and outcomes.</p><p><strong>Results: </strong>Forty-five patients (39 male) received LAMS, and 21 (18 male) received MPS. PNC size and necrotic content were similar between groups. Technical success was 100% in both groups, but clinical success was significantly higher with LAMS (89% vs. 48%; P<0.001). ETN was more frequent in the MPS group (86% vs. 58%; P=0.02), as was the mean number of procedures (6.1 vs. 4.1; P=0.009). MPS was associated with higher mortality (19% vs. 6%), need for surgical necrosectomy (52% vs. 11%), and post-procedure bleeding (24% vs. 11%).</p><p><strong>Conclusion: </strong>LAMS seem to be superior to MPS for ETD of early-phase symptomatic PNC, showing higher clinical success, with fewer complications, procedures and rescue surgical interventions.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"39 1","pages":"71-78"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12850688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146083952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Capillary microvascular function in patients with liver cirrhosis: a nailfold video-capillaroscopy study.","authors":"Ioanna Papagiouvanni, Marieta Theodorakopoulou, Adonis A Protopapas, Theodoros Dimitroulas, Michael Doumas, Emmanouil Sinakos, Pantelis Sarafidis, Ioannis Goulis","doi":"10.20524/aog.2026.1030","DOIUrl":"10.20524/aog.2026.1030","url":null,"abstract":"<p><strong>Background: </strong>Liver cirrhosis is characterized by major circulatory dysregulation, related to an imbalance between several vasoactive agents. Although alterations in intrahepatic and systemic vasculature have been rather well described, the peripheral microcirculation and endothelial function are less well studied. Our aim was to evaluate peripheral microcirculatory function in patients with cirrhosis via nailfold video-capillaroscopy.</p><p><strong>Methods: </strong>We enrolled 60 patients with cirrhosis and 20 controls. All participants underwent nailfold video-capillaroscopy. Capillary density was measured at rest (baseline), after 4-min arterial occlusion (post-occlusive reactive hyperemia) and after 2-min venous congestion.</p><p><strong>Results: </strong>Cirrhotic patients presented lower capillary density than controls at baseline (35.8±3.6 vs. 38±1.1 capillaries/mm², P=0.01), during post-occlusive reactive hyperemia (40.0±4.4 vs. 45.3±1.5 capillaries/mm², P<0.001), and after venous congestion (43.3±4.2 vs. 47.2±1.5 capillaries/mm², P<0.001). Capillary density decreased significantly with deterioration of Child-Pugh class at baseline (Child-Pugh A: 38.0±3.9 vs. Child-Pugh B: 35.6±2.7 vs. Child-Pugh C: 33.9±3.2 capillaries/mm², P<0.001), during post-occlusive reactive hyperemia (43.5±3.4 vs. 39.8±3.0 vs. 36.8±3.9 capillaries/mm², respectively, P<0.001), and after venous congestion (46.7±3.1 vs. 43.0±2.7 vs. 40.1±3.8 capillaries/mm², respectively, P<0.001).</p><p><strong>Conclusions: </strong>Capillary density in all phases was significantly lower in cirrhotic patients compared to controls. Moreover, a lower capillary density was associated with deteriorating Child-Pugh stages, suggesting that increasing severity of cirrhosis is associated with more impaired peripheral microcirculatory function.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"39 1","pages":"23-31"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12850683/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146083914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of the lymphatic network in colorectal cancer: anatomy, molecular drivers and management.","authors":"Dimosthenis Chrysikos, Nikolaos Taprantzis, Amir Shihada, Panagiotis Kanavaros, Theodore Troupis","doi":"10.20524/aog.2026.1089","DOIUrl":"10.20524/aog.2026.1089","url":null,"abstract":"<p><p>Our understanding of the structures and functions of the lymphatic system in colorectal cancer (CRC) has advanced dramatically in recent years. This review aims to outline the information regarding lymphatic drainage of the colon and rectum, as well as our current knowledge of molecular determinants of lymphangiogenesis (e.g., vascular endothelial growth factor-C/-D) and the evaluation of the clinical significance of lymphatic microvessel density in cancer. The review also addresses controversies and innovations in CRC staging, including the impact of lymphovascular invasion on indications for adjuvant chemotherapy, especially in early-stage cancer. A review of current developments in the surgical treatment of CRC (transanal total mesorectal excision and lateral pelvic lymph node dissection) was also conducted, with special reference to the oncological relevance of lymphatic drainage. Knowledge of the complex structures of the lymphatic network is required to establish an individualized risk assessment, and to select the most appropriate surgical strategy in order to optimize the treatment of patients with CRC.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"39 5","pages":"523-533"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13433956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148672963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A guide to healthcare maintenance for the patient with inflammatory bowel disease.","authors":"Celina R Bou Jaoude, Elio R Bitar, Fadi H Mourad, Karthik Gnanapandithan, Francis A Farraye, Jana G Hashash","doi":"10.20524/aog.2026.1091","DOIUrl":"10.20524/aog.2026.1091","url":null,"abstract":"<p><p>Healthcare maintenance plays a vital role in the long-term management of patients with inflammatory bowel disease (IBD), particularly those receiving immunosuppressive therapies. This review emphasizes the importance of maintaining up-to-date vaccinations, regular bone and mental health assessments, and appropriate cancer screening in this population. It also highlights the added complexity of preventive care in immunosuppressed patients, outlining specific modifications to vaccination and screening strategies required to ensure safe and effective disease management. Gastroenterologists and other clinicians involved in IBD care should remain familiar with current guidelines and consistently integrate preventive health measures into routine clinical practice.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"39 5","pages":"509-522"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13433963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148672800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>KRAS</i> p.G12C mutated-targeted treatments in metastatic colorectal cancer: a systematic review and meta-analysis.","authors":"Maria Smaradgi Vlachou, Dimitra Papadimitriou, Dimitrios Ragias, Konstantinos Kamposioras, Panagiotis Filis, Evangelos Lykotsetas, Fani Kapoulitsa, Davide Mauri","doi":"10.20524/aog.2026.1023","DOIUrl":"10.20524/aog.2026.1023","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. The presence of the <i>KRAS</i> G12C mutation in patients with CRC is associated with poor responses to standard therapies and worse outcomes. This study systematically reviewed and analyzed the existing evidence on the efficacy of <i>KRAS</i> G12C inhibitors.</p><p><strong>Methods: </strong>PubMed, Scopus, and ISI Web of Knowledge were searched, along with conference proceedings, posters, and major oncology journals. Eligibility criteria included clinical trials involving adult patients with <i>KRAS</i> G12C-mutant CRC. Data on treatment outcomes, study design, and patient demographics were extracted and analyzed using a random-effects model, with heterogeneity assessed via <i>I</i>2 statistics.</p><p><strong>Results: </strong>Seventeen trials, comprising 663 patients with <i>KRAS</i> G12C-mutant metastatic CRC, were included. Monotherapy with <i>KRAS</i> G12C inhibitors demonstrated an objective response rate of 23%, while combination therapies with agents such as cetuximab and panitumumab showed a higher response rate of 43%. Stable disease rates were also higher in monotherapy (62%) compared to combination therapy (44%). The highest disease control rates were observed with combination therapies (96%). The overall progressive disease rate was lower with combination therapies (1%) than with monotherapies (10%).</p><p><strong>Conclusions: </strong>The results indicate that <i>KRAS</i> G12C inhibitors, particularly in combination with other agents, show promising efficacy in treating metastatic CRC. High heterogeneity across studies suggests variability due to small sample sizes and early-phase trial designs. While preliminary data are promising, further large-scale phase III trials are essential to establish these inhibitors as a standard treatment for <i>KRAS</i> G12C-mutant CRC.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"39 1","pages":"88-98"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12850691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146083937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnetic resonance elastography combined with fibrosis-4 index for diagnosing at-risk metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis of diagnostic test accuracy studies.","authors":"Konstantinos Malandris, Anastasia Katsoula, Tarek Nayfeh, Kalliopi Tsapa, Dimitra Tsapa, Georgios Kalopitas, Aris Liakos, Thomas Karagiannis, Eleni Theocharidou, Emmanouil Sinakos, Georgios Germanidis, Apostolos Tsapas","doi":"10.20524/aog.2025.1010","DOIUrl":"10.20524/aog.2025.1010","url":null,"abstract":"<p><strong>Background: </strong>Patients with metabolic dysfunction-associated steatohepatitis (MASH; nonalcoholic fatty liver disease activity score ≥4) and significant fibrosis (≥F2; at-risk MASH) are at increased risk for disease progression. Magnetic resonance elastography (MRE) combined with the fibrosis-4 (MEFIB) index enables the noninvasive diagnosis of at-risk MASH and significant fibrosis. We assessed the performance of the MEFIB index for ruling in/out both target conditions.</p><p><strong>Methods: </strong>We analyzed studies up to February 2025 assessing the performance of MEFIB index for ruling in (MRE≥3.3 kPa plus FIB-4≥1.6) and out (MRE<3.3 kPa plus FIB-4<1.6) at-risk MASH or significant fibrosis, using liver biopsy as the reference standard. We calculated pooled diagnostic accuracy estimates using bivariate random-effects models.</p><p><strong>Results: </strong>We included 7 studies with 3356 participants. For ruling in at-risk MASH, the MEFIB index yielded a pooled specificity of 0.94 (95% confidence interval [CI] 0.74-0.99), and a positive likelihood ratio (LRp) of 5.3 (95%CI 1.8-15.7). For ruling out at-risk MASH, the MEFIB index had a pooled sensitivity of 0.77 (95%CI 0.62-0.88) and a negative likelihood ratio (LRn) of 0.34 (95%CI 0.23-0.52). For ruling in significant fibrosis, the MEFIB index achieved a summary specificity of 0.93 (95%CI 0.85-0.97) with LRp 8.2 (95%CI 4.5-14.9). For excluding significant fibrosis, the pooled sensitivity and LRn of the MEFIB index were 0.88 (95%CI 0.79-0.94) and 0.16 (95%CI 0.08-0.31), respectively.</p><p><strong>Conclusions: </strong>MEFIB index has acceptable accuracy for diagnosing at-risk MASH and significant fibrosis. Proposed thresholds can be used to identify both target conditions in high prevalence settings and facilitate patient recruitment in clinical trials.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 6","pages":"681-690"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12829540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146050047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ferric carboxymaltose is safe and more effective than oral iron for patients with decompensated cirrhosis and iron deficiency anemia, and demonstrates circulatory, renal and prognostic benefits.","authors":"Ilias Tsiakas, Christina Koustousi, Grigorios Despotis, Dimitrios Biros, Spyridon Tsiouris, Lampros Lakkas, Reveka Konstantopoulou, Dimitrios Christodoulou, Haralampos Milionis, Georgios N Kalambokis","doi":"10.20524/aog.2025.1012","DOIUrl":"10.20524/aog.2025.1012","url":null,"abstract":"<p><strong>Background: </strong>Iron deficiency anemia (IDA) commonly complicates patients with decompensated cirrhosis (DC). We investigated the efficacy of intravenous ferric carboxymaltose (FCM) over oral iron in treating IDA in these patients, the circulatory and renal effects of each treatment, and the prognostic impact of FCM.</p><p><strong>Methods: </strong>We prospectively evaluated non-acutely anemic patients with DC and hemoglobin levels 8-10 g/dL: 58 with IDA (serum ferritin <30 ng/mL) and 90 without IDA. Patients with IDA received oral iron polymaltose (IP) for 3 months and those not achieving hemoglobin increases ≥2 g/dL switched to FCM. Systemic vascular resistance (SVR) as mean arterial pressure/cardiac output ratio, plasma renin activity (PRA), plasma aldosterone, glomerular filtration rate (GFR) and renal blood flow (RBF) were evaluated 3 months after each treatment. All patients with recurrent IDA during follow up received FCM. New/recurrent decompensation and survival rates were assessed in patients with and without IDA.</p><p><strong>Results: </strong>Hemoglobin increased by ≥2 g/dL in 6/51 (11.7%) patients who tolerated IP, compared to 34/45 (75.5%; P<0.001) FCM-treated patients. FCM use was safe and, unlike IP, it significantly increased SVR, GFR and RBF, while significantly reducing PRA and plasma aldosterone (P<0.001). Percentage hemoglobin changes correlated with changes in SVR (r=0.533; P<0.001), GFR (r=0.775; P<0.001) and RBF (r=0.803; P<0.001). FCM-treated patients showed lower 5-year risk of decompensation (P=0.002) and mortality (P=0.006), and lower incidence of hepatorenal syndrome (n=0.03), than patients without IDA.</p><p><strong>Conclusions: </strong>FCM outperforms oral iron in ameliorating IDA in DC patients with DC. Addressing IDA yields positive circulatory, renal and prognostic outcomes.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 6","pages":"691-698"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12829539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146050023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Routine esophagogastroduodenoscopy before upper endoscopic ultrasound for non-luminal indications: clinical value and findings from a large single-center experience.","authors":"Reshad Salam, Zachary Bassler, Yash Hegde, Ola Altahan, Spencer Kitchen, Serge Sorser, Douglas G Adler","doi":"10.20524/aog.2025.1015","DOIUrl":"10.20524/aog.2025.1015","url":null,"abstract":"<p><strong>Background: </strong>Most echoendoscopes are oblique viewing instruments, potentially limiting their value in mucosal evaluation during upper endoscopic ultrasound (EUS) examinations. This raises at least the potential for missed mucosal lesions. While esophagogastroduodenoscopy (EGD) prior to EUS may mitigate this, performing EGD adds both cost and time to upper EUS. This study evaluated the utility of routine EGD before EUS in asymptomatic patients.</p><p><strong>Methods: </strong>We performed a retrospective, single-center, cohort study including 626 patients undergoing EUS for pancreaticobiliary/mediastinal indications over a 5-year period (2017-2022). Exclusion criteria included luminal symptoms or prior upper gastrointestinal surgery. Clinically significant EGD findings and their impact on management were analyzed.</p><p><strong>Results: </strong>Among 568 patients who underwent EGD before EUS, 16.8% (n=95) had clinically significant lesions, including reflux esophagitis (32.7%), Barrett's esophagus (12.7%) and gastritis (17.3%). Additionally, 16.6% (n=94) exhibited findings affecting the feasibility of EUS (e.g., strictures, large hiatal hernias). Management changes occurred in 54.3% of cases, primarily biopsies (54.3%) and medication initiation (36.6%). Only 4.6% had a prior EGD within 6 months of their EUS.</p><p><strong>Conclusions: </strong>Routine EGD before EUS can detect clinically significant mucosal lesions in asymptomatic patients, as well as anatomical factors influencing EUS performance. These findings support considering the incorporation of routine EGD into pre-EUS evaluations to optimize diagnostic accuracy and patient management.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 6","pages":"720-724"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12829533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146050060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of metabolic syndrome in patients with inflammatory bowel disease: a population-level cohort study from the United States.","authors":"Aakash Desai, Himsikhar Khataniar, Jana G Hashash, Priya Sehgal, Francis A Farraye, Gursimran S Kochhar","doi":"10.20524/aog.2025.1011","DOIUrl":"10.20524/aog.2025.1011","url":null,"abstract":"<p><strong>Background: </strong>Epidemiological data on metabolic syndrome (MetS) in patients with inflammatory bowel disease (IBD) are limited.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted using the United States (US) Collaborative Network (TriNetX) to obtain data for patients with IBD between 2010 and 2023. The primary aim of the study was to estimate the prevalence of MetS in ulcerative colitis (UC) and Crohn's disease (CD). Prevalence was further characterized by age, sex, race, disease location, IBD medications, history of surgery, and IBD phenotype.</p><p><strong>Results: </strong>Among 100,890 patients with IBD, metabolic syndrome (MetS) affected 34.4% overall (UC 32.4%, CD 34.3%). Prevalence rose sharply with age (12-14% at 18-39 to 47-50% at ≥65) and was higher in men than women. Rates were greatest among American Indian (CD 45.2%), Black (40%) and Hispanic (38-39%) populations, and lowest in Asian patients (26%). MetS clustered with more severe phenotypes (stricturing CD, prior CD surgery) and was not elevated among patients receiving advanced therapy. MetS was associated with greater systemic corticosteroid use and higher surgery/colectomy risk, while stricture and fistula risks in CD were similar; advanced therapy was not initiated more frequently in CD.</p><p><strong>Conclusion: </strong>Our study provides updated epidemiological estimates of MetS in patients with IBD in the US.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 6","pages":"618-628"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12829534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146050000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}